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Abstract
Introduction: We assessed expression of p85 and p110a PI3K subunits in non-small cell lung cancer (NSCLC) specimens and
the association with mTOR expression, and studied effects of targeting the PI3K/AKT/mTOR pathway in NSCLC cell lines.
Methods: Using Automated Quantitative Analysis we quantified expression of PI3K subunits in two cohorts of 190 and 168
NSCLC specimens and correlated it with mTOR expression. We studied effects of two PI3K inhibitors, LY294002 and NVP-
BKM120, alone and in combination with rapamycin in 6 NSCLC cell lines. We assessed activity of a dual PI3K/mTOR inhibitor,
NVP-BEZ235 alone and with an EGFR inhibitor.
Results: p85 and p110a tend to be co-expressed (p,0.001); p85 expression was higher in adenocarcinomas than squamous
cell carcinomas. High p85 expression was associated with advanced stage and poor survival. p110a expression correlated
with mTOR (r=0.276). In six NSCLC cell lines, addition of rapamycin to LY294002 or NVP-BKM120 was synergistic. Even very
low rapamycin concentrations (1 nM) resulted in sensitization to PI3K inhibitors. NVP-BEZ235 was highly active in NSCLC cell
lines with IC50s in the nanomolar range and resultant down-regulation of pAKT and pP70S6K. Adding Erlotinib to NVP-
BEZ235 resulted in synergistic growth inhibition.
Conclusions: The association between PI3K expression, advanced stage and survival in NSCLC suggests that it might be a
valuable drug target. Concurrent inhibition of PI3K and mTOR is synergistic in vitro, and a dual PI3K/mTOR inhibitor was
highly active. Adding EGFR inhibition resulted in further growth inhibition. Targeting the PI3K/AKT/mTOR pathway at
multiple levels should be tested in clinical trials for NSCLC.
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Introduction
Lung cancer is the leading cause of cancer-related death
worldwide. In the United States alone, about 222,520 new cases
were diagnosed and about 157,300 deaths occurred due to lung
cancer in 2010 [1]. Non-small cell lung cancer (NSCLC)
represents about 80% of all lung cancer. The most common
histologies are adenocarcinoma, squamous cell carcinoma, and
large cell carcinoma. The majority of NSCLC patients are
diagnosed at advanced stage where chemotherapy may improve
survival and palliation of symptoms. However, conventional
chemotherapy provides no cure for advanced NSCLC and has
reached a plateau in efficacy with a median survival of 8–10
months [2]. The addition of new targeted therapies such as
bevacizumab and cetuximab to conventional chemotherapy has
improved the median survival to about 12 months in patients with
good performance status [3,4]. Novel therapeutic approaches are
urgently needed for this common disease.
The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signal-
ing pathway impacts many aspects of cell growth and survival [5].
Alterations of components in the PI3K/AKT/mTOR pathway
can occur at many levels and result in constitutive activation of this
pathway and malignant transformation.
The PI3Ks are a family of enzymes that phosphorylate
phosphatidylinositol biphosphate to phosphatidylinositol triphos-
phate. PI3Ks are most often activated by receptor tyrosine kinase
(RTK) signaling such as through EGFR, IGF1-R and HER2/neu
[6–9]. There are three classes of PI3Ks [10,11]. Class IA PI3K is
the most widely implicated type in cancer and will be referred to as
‘‘PI3K’’ in the remainder of this manuscript. PI3K is a
heterodimer consisting of a p85 regulatory and a p110 catalytic
subunit.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31331Phosphatidylinositol triphosphate mediates the activation of AKT
[11]. AKT, in turn, activates many cellular proteins involved in
protein synthesis, cell growth and survival including mTOR [11–
13].mTOR regulates translation by phosphorylating componentsof
the protein synthesis machinery, including the ribosomal protein S6
kinases (p70
S6K) and 4E-binding protein (4E-BP). Phosphorylation
of4E-BPleadstothe releaseofthe translationinitiation factoreIF4E
which has been demonstrated to exhibit transforming and anti-
apoptotic activites in vitro [13,14]. PTEN reverses PI3K signaling by
dephosphorylating phosphatidylinositol triphosphate [15].
In NSCLC, PI3K/AKT/mTOR signaling is frequently dereg-
ulated due to mutations affecting one of its upstream regulators,
the EGFR receptor, and other components within the pathway
[16]. mTOR pathway components were found to be mutated in
17 genes and in more than 30% of tumors of 188 lung
adenocarcinomas in which exome sequencing was performed
[16]. Increases in gene copy number of PIK3CA, the gene encoding
p110a, and changes in phosphorylated AKT (pAKT) expression
have been described in premalignant bronchial epithelial cells and
NSCLC [17–22]. While mutations in PIK3CA are relatively
infrequent in lung cancer, PIK3CA copy number gain has been
reported in 33.1% of squamous cell lung cancer and in 6.2%
adeno lung cancer in one large series [23]. PI3K signaling has
been shown to mediate bronchioalveolar stem cell expansion
initiated by oncogenic K-RAS [24]. Tumor associated mutations of
p110a are oncogenic in vivo in a mouse model of NSCLC [25].
Overexpression of p85 and p110 a has been demonstrated to
correlate with poor differentiation of primary lung cancers in a
cohort that included 73 cases of NSCLC [26]. Our group has
previously studied the expression of mTOR in NSCLC cohorts
and found an association with improved outcome [27].
Inhibition of PI3K/AKT/mTOR signaling through pharmaco-
logic and genetic approaches induces antiproliferative effects on
certain NSCLC cell lines [17–21] and in lung cancer mouse models
[25,28]. A number of PI3K inhibitors are available for preclinical
research. Older compounds like LY294002 or wortmannin have
anti-tumor activity in preclinical models, but their poor solubility,
narrow therapeutic index and crossover inhibition of other kinases
have limited their clinical application. Newer PI3K inhibitors have
entered early phase clinical trials, and activity of these agents should
be assessed in diseases requiring new approaches, such as NSCLC.
The purpose of our study was to characterize the expression of
p85 and p110 a subunits of Class IA PI3K in two large
independents cohorts of NSCLC specimens and to assess the
association with clinical and pathological variables including
previously published mTOR expression. To obtain more precise,
objective expression measures, we used a newly developed method
of automated, quantitative analysis (AQUA) of tissue microarrays
[29]. As redundant activators of the PI3K/AKT signaling
pathway and negative feedback loops [5] limit the efficacy of
single agent therapies, our next purpose was to study the effects of
targeting the PI3K/AKT signaling pathway at multiple levels in
NSCLC cell lines. We found that higher expression of p85
correlated with poor survival and advanced stage. Expression of
p110a correlated with that of mTOR. Concurrent inhibition of
PI3K and mTOR resulted in synergistic growth suppression.
Adding EGFR inhibition further enhanced the growth-inhibitory
effects of a dual PI3K/mTOR inhibitor.
Materials and Methods
Tissue Microarray (TMA) Construction
A NSCLC cohort was obtained from the H. Lee Moffitt Cancer
Center (Tampa, FL). The Moffitt Cancer Center cohort (MTMA)
contains cores from primary NSCLC tumors of patients diagnosed
between 1991 and 2001. Follow-up time ranged between 0.8
months and 146.4 months, mean follow-up time of 52.3 months.
Age at diagnosis ranged from 40.8 to 84.4 (mean age 69 years).
The cohort included 54.5% males and 45.5% females.
The Yale University cohort (YTMA) was constructed from
paraffin-embedded, formalin-fixed tissue blocks obtained from the
Yale University Department of Pathology Archives. The speci-
mens were resected between 1995 and 2003, with a follow-up
range between 0.1 months and 182.25 months, and a mean follow-
up time of 41 months. Age at diagnosis ranged from 21 to 90
(mean age 65 years). The cohort included 51% males and 49%
females.
TMAs were constructed as previously described [27]. Two
0.6 mm cores were obtained from different, representative areas of
each primary NSCLC specimen and spaced 0.8 mm apart on
glass slides. Cell line pellets consisting of SW480, HT29, A431,
MB435, MCF7, BT474, and SKBR3 were used as controls and
were embedded in the array, as previously described [30]. The
cohorts for MTMA and YTMA were collected with approval of
the institutional review boards and have been used in prior
publications [27,31].
Immunofluorescent staining
TMA slides were stained for each of the two target markers,
PI3K p85 and p110a subunits. Staining was performed for AQUA
as described previously [29–31]. Slides were incubated with the
primary antibody diluted in Tris-buffered saline containing 0.3%
bovine serum albumin at 4uC. Primary antibodies used for the
respective incubations were mouse monoclonal anti-human PI3K
p85, clone 4/PI3-Kinase (Becton Dickinson, Franklin Lakes, NJ)
or rabbit anti-human PI3K p110a clone C73F8 (Cell Signaling
Technology, Danvers, MA), at 1:200 or 1:50 dilutions, respective-
ly. Either goat anti-mouse or goat anti-rabbit horseradish
peroxidase-decorated polymer backbone (Envision, Dako North
America, Carpinteria, CA) was utilized to visualize the target
protein. To create a tumor mask, slides were simultaneously
incubated with either mouse or rabbit anti-cytokeratin at 1:100.
For visualization of cytokeratin staining a goat anti-mouse or anti-
rabbit IgG conjugated to Alexa 546 (Molecular Probes, Inc.) at
1:200 was utilized. The target marker was visualized with Cy5-
tyramide (NED Life Science Products). Coverslips were mounted
with ProLong Gold reagent with 49,6-diamidino-2-phenylindole
(DAPI) (Invitrogen).
Automated Image Acquisition and Analysis (AQUA)
Images were analyzed using algorithms that have been
described [29]. Tumor was distinguished from stromal elements
by cytokeratin signal. Coalescence of cytokeratin at the cell surface
was used to localize cell membrane/cytoplasmic compartment
within the tumor mask, and DAPI was used to identify the nuclear
compartment within the tumor mask. Targets were visualized with
Cy5; this wavelength is used for target labeling because it is outside
the range of tissue autofluorescence. Multiple monochromatic,
high-resolution (1,02461,024 pixel, 0.5-mm) grayscale images were
obtained for each histospot using the 106objective of an Olympus
AX-51 epifluorescence microscope with automated microscope
stage and digital image acquisition driven by a custom program
and macrobased interfaces with IPLabs software (Scanalytics,
Inc.). Images for each histospot were individually reviewed. Two
images were captured for each histospot and for each fluorescent
channel, DAPI, Alexa-546, and Cy5; one image in the plane of
focus and one 8 ı `m below it. The compartmentalization and
quantification of the target protein signal within each pre-defined
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the Alexa-546 signal representing cytokeratin staining was utilized
to generate an epithelial cell mask that excludes all other stromal
elements. This signal is binary gated in order to identify whether a
pixel is within the tumor mask (on) or not (off); all white pixels are
part of that mask and all black pixels are not part of this
compartment. Similarly, the nuclear compartment is defined as
pixels that demonstrate DAPI staining within the plane of focus
and within the region defined by the tumor mask. The DAPI
image is also binarized to generate a mask of all nuclei within the
sample by subtracting out overlapping pixels with the cytoplasmic
mask; all white pixels are part of this mask while all black pixels are
not. To ensure that only the target signal from the tumor and not
the surrounding elements is analyzed, the RESA/PLACE
algorithms were utilized. The RESA algorithm provides an
adaptive thresholding system. In general, formalin-fixed tissues
can exhibit autofluorescence and sometimes analysis can give
multiple background peaks. The RESA algorithm establishes the
predominant peak and then sets a binary mask threshold at a
slightly higher intensity level. RESA eliminates all out-of-focus
information by subtracting a percentage of the out-of-focus image
from the in-focus image, based on a pixel-by-pixel analysis of the
two images. This eventually allows more accurate assignment of
pixels of adjacent compartments. Finally, we utilize the PLACE
algorithm to assign each pixel of each image to a specific
subcellular compartment. All pixels that cannot be accurately
assigned to a compartment with a degree of confidence of 95% are
ultimately excluded. Additionally, all pixels for which intensities
are too similar in the nuclear and membrane compartments and
therefore cannot be accurately assigned are also excluded. PI3K
expression was automatically determined from Cy5 channel
images to obtain relative pixel intensity for the signal emanating
from the plane of focus. First, each pixel is assigned to a subcellular
compartment or is excluded as described above. An AQUA score
for any sub-cellular compartments is usually calculated as the
average AQUA score from each of the individual pixels included
in the selected compartment; the target signal (p85 or P110a) from
the pixels within the cytoplasm was normalized to the area of
tumor mask and scored on a scale of 0–255 (the AQUA score).
Histospots were excluded if the tumor mask represented less than
5% of the total histospot area.
Statistical Analysis
JMP version 5.0 software was used (SAS Institute, Cary, NC).
The prognostic significance of parameters was assessed using the
Cox proportional hazards model with progression free survival
and overall survival as an end point. Univariate survival analyses
were depicted using the Kaplan-Meier method. The association
between continuous AQUA scores and other clinical/pathological
parameters was assessed by analysis of variance. All reported p-
values are based on two-sided significance testing. ANOVA and t-
test were used to compare continuous measurements.
Cell Lines and Western Blots
Squamous carcinoma cell line H2170 and adenocarcinoma cell
lines H1650, HCC2935 and HCC827 were kindly provided by
Drs. John Minna and Michael Peyton (Southwestern University).
Squamous carcinoma cell lines SK-MES-1 and SW900 were
obtained from American Type Tissue Culture. The characteristics
of each cell line including mutational status of PIK3CA, K-RAS and
EGFR are shown in Table S1. The adenocarcinoma cell lines
H1650, HCC2935 and HCC827 have wild-type PIK3CA and K-
RAS but mutant EGFR. All squamous carcinoma cell lines SK-
MES-1, H2170 and SW900 have wild-type EGFR and wild-type
PIK3CA. SK-MES-1 and H2170 have wild-type K-RAS. SW900
has mutant K-RAS. We were interested in comparing the effects of
PI3K inhibition in adenocarcinoma to squamous carcinoma cell
lines and comparing with EGFR mutant to EGFR wild-type cell
lines. All human lung cancer cell lines were cultured under
standard conditions (37uCi n5 %C O 2 atmosphere) and grown in
RPMI (Gibco
TM, Invitrogen Corp, Grand Island, NY) supple-
mented with 10% FBS. HBE135-E6E7 cell line, a non-
transformed bronchoalveolar cell line, was purchased from the
American Type Culture Collection (Manassas,VA) and grown in
Keratinocyte-Serum Free medium supplemented with 5 ng/ml
human recombinant EGF, 0.05 mg/ml bovine pituitary extract,
0.005 mg/ml insulin and 500 ng/ml hydrocortisone.
Protein concentrations of cell lysates were calculated by the
BCA (Bicinchoninic Acid) assay (Pierce Biotechnology, Rockford,
IL). Proteins (50 mg) were diluted in a sample buffer [2.5% SDS,
10% glycerol, 5% b-mercapto-ethanol, 50 mM Tris (pH=6.8)
and 0.1% bromophenol blue] and subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Western
blotting was performed by standard methods using the following
primary rabbit anti-human antibodies: phosporylated AKT
(Ser
473), phosphorylated p70S6K (Thr
389), PI3K p110a, phos-
phorylated S6 Ribosomal Protein (Ser
235/236), PARP (Cell
Signaling Technologies, Danvers, MA) at 1:1000, and mouse
monoclonal anti-human PI3K p85 or anti-caspase-2 (Becton
Dickinson, Franklin Lakes, NJ) at 1:1000. A monoclonal mouse b-
Actin (A2066 or A5441, SIGMA, 1:200 or 1:5000 respectively)
was utilized as a control to standardize sample loading. Detection
of proteins was done with peroxidase-conjugated anti-mouse or
anti-rabbit IgG secondary antibodies (1:5000, Jackson ImmunoR-
esearch Laboratories) and ECL (PerkinElmer).
Antineoplastic Agents and Cell Viability Assays
For cell viability assays, 1610
3 cells were plated in triplicate in a
96 well microtiter plate (BD Bioscience) and allowed to grow for
24 hours to an approximate confluence of 30%. For drug
inhibition studies, NVP-BEZ235 and NVP-BKM120 (Novartis
Pharmaceuticals, Basel, Switzerland) and LY294002 (LC Labora-
tories, Woburn MA) were used to treat lung cells at various
concentrations. For combination experiments, the mTORC1
inhibitor, rapamycin and EGFR inhibitor erlotinib (LC Labora-
tories) were utilized.
Cell viability was evaluated at 72 hours using the CellTiter-
Glo
TM Luminescent Cell Viability Assay, according to the
manufacturer’s instructions (Promega, USA); an equal volume of
the Cell Titer-Glo
TM reagent was added to the wells and after a
10 minute incubation, luminescence was recorded using a
Victor
TMX multilabel plate reader (Perkin Elmer). The IC50
values were determined by the XLfit software (MathIQ version
2.2.2, IDBS).
Synergistic Drug Effect Analysis
The Chou and Talalay combination index analysis method was
utilized to analyze results from combinatory drug experiments
[32]. NVP-BKM120 and LY294002 were used in combination
with the mTOR inhibitor, rapamycin. NVP-BEZ235 was
combined with erlotinib, at their respective single drug IC50 or
IC25 concentrations. The IC50 and IC 25 values of each drug were
first obtained from single-drug viability assays and then utilized to
design drug combination experiments. The level of synergism was
assessed over a wide range of drug concentrations, focusing on
concentrations below or at the IC50 for either drug alone. Our
results were analyzed for synergistic, additive, or antagonistic
effects using CalcuSyn software (Biosoft, Ferguson, Missouri,
Targeting PI3K Pathway in Lung Cancer
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of less than 0.9, additive effect by a CI between 0.9 and 1.1, and
antagonistic effect by CI greater than 1.1.
Results
Expression of PI3K p85 and p110a ´ subunits in human
lung cancer specimens
For the MTMA, 166 and 190 specimens were fully assessable
with regard to PI3K p85 and p110a subunit expression,
respectively. PI3K did not show significant nuclear staining for
either subunit, and we therefore analyzed only the cytoplasmic
compartment. Staining patterns within the tumor mask within a
histospot were highly homogenous for both subunits. AQUA
scores ranged from 7.12 to 127.04 (mean, 37.68; median, 33.47)
for the p85 subunit, and from 5.43 to 138.56 (mean, 24.35;
median, 20.26) for the p110a subunit. An example of AQUA
staining of histospots for p85 and p110a expression is shown in
Figure 1 and Table S2. Histospots were deemed un-
interpretable if they had insufficient tumor cells, loss of tissue in
the spot, or an abundance of necrotic tissue. Specimens with less
than 5% tumor area per spot were not included in the AQUA
analysis.
We assessed the associations between PI3K subunit expression
and histologic subtype, by unpaired t-tests. Expression of both the
p85 and the p110a subunits were significantly higher in
adenocarcinomas than in squamous cell carcinomas (P,0.0001
for p85 and P=0.0356 for p110a), as shown in Figure 2, panel
A&B .
To validate the association between the PI3K subunits and
adenocarcinoma, the YTMA was employed. As opposed to the
MTMA which was primarily stage I (A and B) lung cancer (92%),
the YTMA included 55% stage I, and 45% stage II–IV (17%, 19%
and 9% stage II, III, IV respectively) lung cancer. For the YTMA
PI3K p85 and p110a subunit expression was interpretable for 163
and 168 specimens, respectively. The AQUA scores for this cohort
ranged from 4.18 to 120.73 (mean, 35.31; median, 32.70) for the
p85 subunit, and from 9.17 to 86.91 (mean, 38.12; median, 35.17)
for the p110a subunit. Unpaired t-test confirmed the findings from
the MTMA; expression of the p85 subunit and the p110a subunit
were significantly higher in adenocarcinomas than in squamous
cell carcinomas (P,0.0002 for p85 and P=0.0266 for p110a), as
shown in Figure 2, panel C & D. High p85 and p110a subunit
expression correlated with advanced disease stage of disease
(P=0.0075, P=0.0093, respectively), but not with age and gender
(not shown).
By Cox univariate survival analyses of continuous AQUA
scores, we found that high p85 expression correlated with
decreased survival (P=0.0198). AQUA provides continuous
output scores, rather than categories of ‘‘high’’ or ‘‘low’’, as
determined by pathologists interpreting standard immunohisto-
chemistry. To visualize the association between continuous PI3K
scores and survival, AQUA scores were dichotomized by the
median, reflecting the use of routine statistical divisions in the
absence of underlying justification for division of expression.
Kaplan-Meier survival curves were generated for PI3K p85
subunit expression and survival and P-values were obtained by the
Mantel-Cox log-rank method. As shown in Figure 2, panel E &
F, we found a significant association between high p85 expression
and poor survival (P=0.0075). No association was found between
p110a expression and survival.
On multivariate analysis p85 expression did not retain its
independent predictive value, presumably due to its association
with histologic subtype and stage. The only variable associated
with survival by multivariate analysis was Stage (P=0.0000). No
such association between p110a subunit expression and survival
was noted.
Coexpression of PI3K p85 or p110a ´ with mTOR in human
lung tumors
The association between the previously published mTOR
expression [27] and p85 and p110a subunits of PI3K was
assessed. Using the Spearman rank correlation test, mTOR
expression was associated with p110a expression (r=0.276,
p=0.0006), while no association was found between levels of
mTOR and p85 subunit.
In vitro activity of NVP-BKM120 and LY294002 in lung cell
lines
Due to the association between PI3K and advanced stage and
poor survival, the in vitro activity of PI3K inhibitors was studied in
six human lung cancer cell lines. Two PI3K inhibitors were
utilized; we studied NVP-BKM-120, a clinical quality PI3K
inhibitor being developed by Novartis, and LY294002, a
commercially available compound that has been widely used to
study PI3K inhibition in the preclinical setting. Cells were treated
with either NVP-BKM120 at concentrations ranging from
0.01 nM to 8,200 nM or LY294002 at concentrations ranging
from 6.4 nM to 20,000 nM. All experiments were done in
triplicate. After 72 hours incubation, cell viability was evaluated,
and the IC50 was calculated for each cell line, and averaged for
repeat experiments. As shown in Table 1, the IC50 for NVP-
BKM120 and LY294002 inhibition ranged from 716 nM to
1265 nM and 4123 nM to 11925 nM, respectively.
To test whether growth inhibition inflicted by NVP-BKM120
and LY294002 are specific or at least enhanced in malignant
compared to normal cells, we used an immortalized, non-
transformed bronchoaveolar cell line, HBE135-E6E7. These cells
were derived from normal bronchial epithelium taken from a man
undergoing lobectomy for squamous cell carcinoma [33]. NVP-
BKM120 and LY294002 had little effect on the normal
bronchoaveolar cells at concentrations approximately 10 and 5
fold the average IC50 of these two drugs, respectively, in NSCLC
cells. 13% growth inhibition was seen at 10 mM NVP-BKM120
but an IC50 could not be reached at higher concentrations, and a
mere 25% growth inhibition was obtained with 50 mM LY294002
treatment.
Given that the expression levels of drug targets sometimes
predict drug sensitivity, we studied the association between the
degree of sensitivity/resistance to NVP-BKM120 and LY294002
and PI3K levels. We assessed the two PI3K subunits and total and
phosphorylated AKT by immunoblotting. No clear association
was found between pretreatment levels of PI3K (p85 or p110a)o r
total and phosphorylated AKT and sensitivity/resistance to NVP-
BKM120 or LY294002 (Figure S1).
Synergism between PI3K and mTOR inhibitors
Resistance to PI3K inhibition has been noted in different
diseases and attributed to numerous mechanisms. Constitutive
PI3K pathway activation could result from AKT activation by
mTOR-C2 or mTOR activation by MAP kinase pathway
members despite specific PI3K drug inhibition. Due to the co-
expression between p110a and mTOR seen in our clinical
specimens, we studied synergism between the mTOR inbitor
rapamycin and NVP-BKM120 and rapamycin and LY294002.
Concentrations of 1000 and 500 nM of NVP-BKM120 were
combined with a range of concentrations of rapamycin (1, 10 and
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31331Figure 1. Examples of positive and negative staining of histospots for the p85 (Panel A and B, respectively) and p110a (Panel C and
D, respectively) subunits. Anti-PI3K conjugated to Cy5 is used to measure PI3K subunit levels (lower left quadrants, magnification 610). Anti-
cytokeratin conjugated to Cy3 is used to identify tumor cells within the histospot (upper right quadrants). Holes are filled in to create a tumor mask
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six cell lines at all concentrations of NVP-BKM120 with all three
concentrations of rapamycin, and in the sixth cell line (H1650),
synergy was seen at higher concentrations of NVP-BKM120
(Figure 3 and Tables S3 and S4). We then studied synergism
between LY294002 and rapamycin. Concentrations of 5000 and
2500 nM of LY294002, were combined with a range of
concentrations of rapamycin (1, 10 and 100 nM) in six lung cell
lines. Synergism was seen in all six cell lines at all concentrations of
LY294002 with all three concentrations of rapamycin as shown in
Table S3. Figure 3 shows the synergism graphically, using
H2170 and SW900 as an example. Notably, the differences seen in
viability when adding 1 nM, 10 nM or 100 nM rapamcyin were
fairly similar.
Activity of a dual PI3K/mTOR inhibitor in NSCLC cell lines
Given the synergism seen between PI3K inhibitors and
rapamycin in lung cancer cell lines, a dual PI3K/mTOR inhibitor
that has been given to solid tumor patients in phase I clinical trials,
NVP-BEZ235, was studied. In all six lung cancer cell lines the
Figure 2. Unpaired t-tests showing the association between PI3K levels in NSCLC specimens and histological subtypes. Significantly
higher expression of PI3K p85 subunit is seen in adenocarcinoma tumors, in the Moffitt Cancer Cohort and the Yale University Cohort, respectively
(Panel A & C). Significantly higher expression of PI3K p110a subunit in adenocarcinoma tumors is seen in the Moffitt Cancer Cohort and the Yale
University Cohort, respectively (Panel B & D). Kaplan Meier curves showing an association between PI3K subunit expression and decreased survival
for p85 (Panel E) but not for p110a (Panel F).
doi:10.1371/journal.pone.0031331.g002
(right lower quadrants). DAPI is used to identify nuclei (upper left quadrants). The nuclear compartment within the tumor mask is then subtracted
from the mask to create a cytoplasmic compartment (not shown). The right panels are 406magnifications of PI3K p85 and p110a subunit positive
and negative staining, respectively.
doi:10.1371/journal.pone.0031331.g001
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31331Table 1. IC50 of NVP-BKM120, LY294002, and NVP-BEZ235 in a panel of six lung cancer cell lines.
Histological Subtype Cell Line IC50’s (nM)
NVP-BKM120 LY294002 NVP-BEZ235
Squamous Cell Carcinoma SK-MES 1091 4123 36
H2170 821 9733 22
SW900 1128 11652 50
Adenocarcinoma H1650 1248 10850 23
HCC2935 716 9463 9
HCC827 1265 11925 130
doi:10.1371/journal.pone.0031331.t001
Figure 3. Combinations of either NVP-BKM120 and rapamycin or LY294002 and rapamycin in H2170 (left) and SW900 (right) lung
cancer cell lines. Cells were treated with descending nanomolar concentrations of the PI3K inhibitor NVP-BKM120 or LY294002, alone or combined
with 1 nM, 10 nM or 100 nM rapamycin for 72 hours and viability was measured with the Cell Titer Glo assay. The bars show viability as a percentage
of viable cells relative to untreated cells. Three separate experiments were performed and each condition was measured in three replicate wells.
doi:10.1371/journal.pone.0031331.g003
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while no effect was seen in HBE135-E6E7 cells, even at
concentrations as high as 1000 nM or twenty times the average
IC50 observed in NSCLC cell lines (Table 1). These results
suggest that NSCLC growth and survival mediated by a broad
range of molecular factors are selectively sensitive to inhibition of
PI3K by NVP-BEZ235. Targets of NVP-BEZ235 (pAKT,
pP70S6K and pS6) were determined by immunoblot analysis in
cells with up to 24 hours drug exposure. Any drug exposure
beyond 24 hours resulted in significant amount of dead cells and
debris and would have limited the interpretability. pAKT,
pP70S6K and pS6 decreased with exposure to the drug in a
time-dependent fashion, as shown by immunoblot analysis in
Figure 4, panel A for H2170 and HCC2935 cell lines. Relative
to untreated cells, pAKT, pP70S6K, and pS6 were down-
regulated with NVP-BKM120, LY294002, and NVP-BEZ235.
NVP-BEZ235 was previously shown to cause PARP cleavage
and induce apoptosis through activation of caspase-2, but not
caspases-8, -9, and -10 [34]. We therefore studied the effect of
NVP-BEZ235 on PARP cleavage and caspase-2 activation in two
most sensitive lung cancer cell lines, HCC2935 and H2170. As
shown in Figure 4, panel B NVP-BEZ235 treatment results in
PARP cleavage and modest caspase-2 activation. Cleaved caspase-
2 was not detected by western blotting in this assay.
Synergism between the dual PI3K/mTOR inhibitor NVP-
BEZ235 and the EGFR inhibitor erlotinib in NSCLC cell
lines
Our results so far show that mTOR blockade is necessary to
enhance the inhibition of the PI3K pathway. Given that inhibiting
only one or two steps of the survival and proliferation pathways
often proves to be therapeutically insufficient due to the various
escape mechanisms, we studied the efficacy of multi-level targeting
by adding EGFR tyrosine kinase inhibition to dual PI3K/mTOR
inhibition in the same set of six NSCLC cell lines. Cells were
treated with the PI3K inhibitor NVP-BEZ235 alone or combined
with erlotinib, at their respective single drug IC50, IC25 or IC10
concentrations (Table 1 and Tables S5 and S6), and viability
was measured at 72 hours with the Cell Titer Glo assay. As shown
in Table S6, synergism was seen in all six cell lines studied,
including SW900 and SK-MES-1 which are highly resistant to
erlotinib alone. Notably, in all four erlotinib sensitive cell lines
Figure 4. Effects of NVP-BKM120, LY294002 and NVP-BEZ235 on pAKT, pP70S6K, and pS6 expression in HCC2935 and H2170 lung
cancer cell lines. Panel A: HCC2935 and H2170 cells were treated with the indicated concentration of NVP-BKM120, LY294002 or NVP-BEZ235 for 1,
6 or 24 hours and harvested at these time points. Cells were lysed and proteins were extracted, electrophoresed and probed for expression of
phosporylated AKT (Ser
473), phosphorylated p70S6K (Thr
389) and phosphorylated S6 Ribosomal Protein (Ser
235/236). Protein gel loading was assessed
by expression of b-Actin. Panel B: Effects of NVP-BEZ235 on apoptosis in HCC2935 and H2170 lung cancer cell lines. Treatment of H2170 and
HCC2935 cells with ascending concentrations of NVP-BEZ235 resulted in dose-dependent PARP cleavage and caspase-2 induction.
doi:10.1371/journal.pone.0031331.g004
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more enhanced at higher concentrations of erlotinib (Table S6).
A graphic example of the combined effect of these two drugs in
H2170 and HCC2935 is shown in Figure 5 and Table S7.O f
note, the majority of erlotinib concentrations used in these
experiments are well below the reported steady-state level of
erlotinib achieved in actual patients which has been reported as
1200+/2620 ng/ml [35]. This translates into 2797.2+/
21445.2 nM of erlotinib.
Discussion
Deregulation of the PI3K/AKT/mTOR signaling pathway has
been demonstrated in NSCLC. In this study, we assessed the
expression of PI3K subunits p85 and p110a in NSCLC tumor
specimens.Inthetwocohortswestudiedtherewashigherexpression
of p85 in adenocarcinoma compared to squamous cell carcinoma
across all stages. High p85 expression was prognostic of decreased
survival on univariate analysis, but not on multivariate analysis,
presumably due to the strong association with disease stage.
Mutations or copy number gains of PIK3CA, the gene encoding
p110a, have been described in lung cancer, and a limitation of our
study is that the PIK3CA genetic status is unknown in the tumor
specimens ofourcohorts.However, the expression of p85 might be a
more valuable indicator to study, as several studies have demon-
strated that p110a that is expressed in excess of p85 is unstable and
rapidly degraded when not bound to p85 [36–38]. Immunohisto-
chemical staining of tumor specimens for p110a is therefore likely
going to underestimate the impact of p110a and changes in PIK3CA
status. Furthermore, p85 has been proposed to have a regulatory
function by associating with proteins other than p110 a such as IRS-
1 and PTEN [38,39]. Even tumor suppressor properties of p85 have
been proposed based on observations in mice with a liver-specific
deletion of the PiK3r1 gene [40]. We also cannot rule out the
possibility that other isoforms of the catalytic subunit such as p110b,
p110d and p110c might be involved in NSCLC as it has been
described in other cancers. For instance, a recent study suggested a
critical role for p110c in pancreatic cancer [41].
Our findings are consistent with previous observations in a
smaller cohort that included 73 cases of primary NSCLC which
indicated that high p85 expression was associated with higher
tumor grade and metastatic disease [26]. By using a quantitative
method (AQUA), we were able to confirm the correlation between
high p85 expression and poor survival and higher stage in a large
independent cohort of NSCLC patients.
The association between high p85 expression and disease
aggression demonstrated by our data and corroborated by results
published by other investigators pointing to the role of PI3K in
cancer, suggests that PI3K might be a valuable therapeutic target in
NSCLC and warrants further investigation using novel and more
effective PI3K inhibitors, such as those studied here. However,
resistance to PI3K inhibition has been attributed to numerous
mechanisms including negative feedback loops. One of the events
downstream of PI3K activation is the activation of AKT through
phosphorylation on Thr
308 and Ser
473. Increasing evidence has
emerged that a rapamycin-insensitive mTOR complex is the kinase
responsible for AKT activation resulting from phosphorylation on
Ser
473 [42,43] which paradoxically allows mTOR to be both
upstream and downstream of itself [44]. It has been suggested that
targeting the PI3K pathway at multiple sites might be required to
interrupt feedback loops to achieve optimal outcomes [5]. We were
able to demonstrate synergistic effects by co-targeting PI3K and
mTOR in NSCLC cell lines using LY294002, a commercially
available PI3K inhibitor, and NVP-BKM120, a novel clinical
quality PI3K inhibitor, alone and in combination with rapamycin.
This study is the first report of the effects of NVP-BKM120 in
NSCLC cell lines. A recently completed phase 1 study of NVP-
BKM120 included two patients with pre-treated lung cancer with
one patient remaining on study for more than 8 months [45].
While our AQUA data show a higher expression of p85 and
p110a in adenocarcinoma compared to squamous cell carcinoma,
it does not appear in the limited number of cell lines that were
studied that adenocarcinoma cell lines are more sensitive to PI3K
inhibitors than squamous carcinoma cells.
m-TOR inhibitors like rapamycin and its analogues (rapalogs)
have cytostatic properties in preclinical models [46]. However,
Figure 5. Combinations of either of NVP-BEZ235 and Erlotinib in H2170 (left) and HCC2935 (right) lung cancer cell lines. H2170 and
HCC2935 cells were treated with the PI3K inhibitor NVP-BEZ235 alone or combined with Erlotinib at their respective single drug nanomolar IC50 or
IC25 concentrations. Viability was measured at 72 hours with the Cell Titer Glo assay. The bars show viability as a percentage of viable cells relative to
untreated cells. Three separate experiments were performed and each condition was measured in three replicate wells.
doi:10.1371/journal.pone.0031331.g005
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alone to patients with NSCLC, presumably because they interrupt
negative feedback loops that down-regulate PI3K signaling,
causing paradoxical up-regulation of pro-survival signaling
pathways. Our data suggest that rapalogs in combination with a
PI3K inhibitor may limit this up-regulation and could act as
sensitizers to direct PI3K inhibition in NSCLC. This finding is
consistent with previous reports of activity by combining PI3K and
mTOR inhibitors in various types of cancer cells [47,48]. Our
observation that minimal mTOR inhibition is sufficient to achieve
synergism with direct PI3K inhibitors is very important, as this
may translate into better clinical tolerability without sacrificing
efficacy of this drug combination.
Dual inhibitors of PI3K and mTOR have demonstrated
promising activity in a number of malignancies [34,48,49].
NVP-BEZ235, a novel dual inhibitor of PI3K and mTOR, was
highly active in all NSCLC cell lines tested with IC50s in the
nanomolar range and led to downregulation of pAKT and
pP70S6K. This result is consistent with the effects of NVP-
BEZ235 in NSCLC cell lines recently published by other
investigators [50–52]. In addition, we were able to demonstrate
that NVP-BEZ235 resulted in PARP cleavage and caspase-2
activation. This is consistent with previous studies demonstrating
that NVP-BEZ235 induced apoptosis through activation of
caspase-2 but not caspases-8, -9 and -10 [34,48]. Our results with
NVP-BEZ235 are consistent with previous studies showing
antiproliferative effects of NVP-BEZ235 in a transgenic mouse
model of lung cancer [25]. NVP-BEZ235 has now entered early
phase clinical trials for solid tumors. Five patients with lung cancer
were included in a recently completed Phase I study with two of
them demonstrating response by CT and PET criteria to NVP-
BEZ325 [53].
In the limited number of lung cancer cell lines that we studied
the response to co-inhibition by PI3K inhibitors and rapamycin
or to the dual inhibitor, NVP-BEZ235, was independent of wild-
type or mutant EGFR status. This observation differs somewhat
from a previous report by Faber et al. [54] describing insufficient
antiproliferative effects of NVP-BEZ235 in the EGFR mutant
NSCLC cell line HCC827. However, it has to be noted that
HCC827 – unlike the other cell lines with EGFR mutations –
was also the cell line least sensitive to NVP-BEZ235 in our
hands.
We explored the possibility of targeting the PI3K/AKT
pathway at multiple levels by adding the direct EGFR tyrosine
kinase inhibitor erlotinib to the dual inhibition of PI3K and
mTOR by NVP-BEZ235. Erlotinib is approved by the FDA as
single agent therapy for NSCLC after first and second line
chemotherapy [55], however the response rates are low at an
average of 8.9% and the median duration of response is modest at
7.9 months. While we observed a wide range of IC50s for erlotinib
which spanned four logs between the most sensitive and the most
resistant cell lines, erlotinib potentiated the growth inhibition by
NVP-BEZ235 in all cell lines studied. These results support a
potential therapeutic role of co-targeting of EGFR and the PI3K
pathway and suggest that this approach should be evaluated
further for patients with NSCLC. Of note, the concentrations of
erlotinib used in majority of these experiments were well below the
reported steady state level of erlotinib achieved in actual patients
[35].
In summary, here we showed that PI3K expression is associated
with advanced stage and decreased survival in NSCLC, suggesting
that it might be a good drug target for this disease. The p110a
subunit was strongly co-expressed with mTOR. Concurrent
inhibition of PI3K and mTOR was synergistic in all NSCLC cell
lines studied and resulted in growth inhibition and apoptosis. It
appeared that minimal amount of rapamycin in the nanomolar
range was sufficient to potentiate the effect of the PI3K inhibitors,
LY294002 and NVP-BKM-120. This could potentially translate
into decreased toxicity and better clinical tolerability of the drug
combination. Dual inhibition of PI3K and mTOR by NVP-BEZ-
235 is promising and should be further evaluated in clinical trials
for patients with NSCLC alone and in combination with EGFR
inhibitors.
Supporting Information
Figure S1 Expression of PI3K (p85 or p110a) and total
and phosphorylated AKT in NSCLC lysates. Pretreatment
PI3K, AKT and phosphorylated AKT levels were variable among
cell lines and there is no apparent association between these levels
and sensitivity/resistance to NVP-BKM120 or LY294002.
(TIF)
Table S1 Characteristics of cell lines. References for
mutational status of cell lines: http://www.sanger.ac.uk/perl/
genetics/CGP/cosmic/ http://www.atcc.org.
(XLS)
Table S2 AQUA Score Distribution.
(XLS)
Table S3 Combination Indices (CI) for NVP-BKM120
and rapamycin or LY294002 and rapamycin in six lung
cancer cell lines. (Synergistic combinations are highlighted in
blue.)
(XLS)
Table S4 Viability data for NVP-BKM120 and rapamy-
cin or LY294002 and rapamycin in H2170 and SW900
lung cancer cell lines.
(XLS)
Table S5 IC50 of Erlotinib in a panel of six lung cancer
cell lines.
(XLS)
Table S6 Combination Indices (CI) for NVP-BEZ235
and Erlotinib in six lung cancer cell lines. (Synergistic
combinations are highlighted in blue.)
(XLS)
Table S7 Viability data for NVP-BEZ235 and Erlotinib
in H2170 and HCC2935 cancer cell lines.
(XLS)
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